Immune cells engineered to fight deadly childhood brain tumors enter human trials
NCT ID NCT07501156
First seen Apr 06, 2026 · Last updated Jun 16, 2026 · Updated 10 times
Summary
This study tests a new treatment for a rare and aggressive brain cancer called diffuse midline glioma (including DIPG). The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a specific marker (H3K27M). The trial aims to see if this approach is safe and can shrink tumors in 30 patients aged 2 to 70 whose cancer has returned or not responded to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA OR DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.